95307-71-4

Basic information

• Product Name: Ethanone, 1-[2-hydroxy-4-(phenylmethoxy)phenyl]-2-(4-methoxyphenyl)-
• CAS NO: 95307-71-4
• Molecular Formula: C22H20O4
• Molecular Weight: 348.398
• Mol File: 95307-71-4.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-[2-hydroxy-4-(phenylmethoxy)phenyl]-2-(4-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[2-hydroxy-4-(phenylmethoxy)phenyl]-2-(4-methoxyphenyl)-(95307-71-4)
• EPA Substance Registry System: Ethanone, 1-[2-hydroxy-4-(phenylmethoxy)phenyl]-2-(4-methoxyphenyl)-(95307-71-4)

Safety Data

• Hazardous Substances Data: 95307-71-4(Hazardous Substances Data)

Upstream product

• 104-47-2 p-methoxybenzylnitrile 
• 3769-41-3 3-Benzyloxyphenol 
• 108-46-3 recorcinol 
• 104-01-8 4-Methoxyphenylacetic acid 
• 487-49-0 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 100-44-7 benzyl chloride 

Downstream Products

• 1621-59-6 7-benzyloxy-3-(4-methoxyphenyl)-1-benzopyran-4-one 
• 746640-16-4 3-(4-methoxyphenyl)-7-(phenylmethoxy)-2-[(pyridin-4-ylmethyl)thio]-4H-1-benzopyran-4-one 
• 746640-09-5 3-(4-methoxyphenyl)-7-(phenylmethoxy)-2-[(phenylmethyl)thio]-4H-1-benzopyran-4-one 
• 10499-15-7 7-benzyloxy-3-(4-methoxyphenyl)-3H-benzopyran-4-one 
• 56407-03-5 3-(4-methoxyphenyl)-4-hydroxy-7-benzyloxy-2H-chromen-2-one 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 3-substituted 4-anilino-coumarin derivatives as antitumor agents

Various 3-substituted 4-anilino-coumarin derivatives have been designed, synthesized and their anti-proliferative properties have been studied. The in vitro cytotoxicity screening was performed against MCF-7, HepG2, HCT116 and Panc-1 cancer cell lines by MTT assay. Most of the synthesized compounds exhibited comparable anti-proliferative activity to the positive control 5-Fluorouracil against these four tested cancer cell lines. Among the different substituents at C-3 position of coumarin scaffold, 3-trifluoroacetyl group showed the most promising results. Especially, compounds 33d (IC50?=?16.57, 5.45, 4.42 and 5.16?μM) and 33e (IC50?=?20.14, 6.71, 4.62 and 5.62?μM) showed excellent anti-proliferative activities on MCF-7, HepG2, HCT116 and Panc-1 cell lines respectively. In addition, cell cycle analysis and apoptosis activation revealed that 33d induced G2/M phase arrest and apoptosis in MCF-7 cells in a dose-dependent manner. Low toxicity of compounds 33d and 33e was observed against human umbilical vein endothelial cells (HUVECs), suggesting their acceptable safety profiles in normal cells. Furthermore, the results of in silico ADME studies indicated that both 33d and 33e exhibited good pharmacokinetic properties.

Induction of targeted osteogenesis with 3-aryl-2H-benzopyrans and 3-aryl-3H-benzopyrans: Novel osteogenic agents

Development of target oriented chemotherapeutics for treatment of chronic diseases have been considered as an important approach in drug development. Following this approach, in our efforts for exploration of new osteogenic leads, substituted 3-aryl-2H-be

In vivo evaluation of substituted 3-phenyl,7-methoxy-benzopyrans as modified estrogens

Substituted 3-phenyl,7-methoxy-benzopyran derivatives and vitamin D 3 (cholecalciferol, 1) were evaluated for their estrogen agonistic and antagonistic activities in immature female Sprague-Dawley rat model. The benzopyran derivatives 17 and 18